Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
Add more filters










Publication year range
1.
Oncogene ; 26(41): 6093-8, 2007 Sep 06.
Article in English | MEDLINE | ID: mdl-17420726

ABSTRACT

Carcinomas are tumors of epithelial origin accounting for over 80% of all human malignancies. A substantial body of evidence implicates oncogenic signaling by receptor tyrosine kinases (RTKs) in carcinoma development. Here we investigated the expression of Sef, a novel inhibitor of RTK signaling, in normal human epithelial tissues and derived malignancies. Human Sef (hSef) was highly expressed in normal epithelial cells of breast, prostate, thyroid gland and the ovarian surface. By comparison, substantial downregulation of hSef expression was observed in the majority of tumors originating from these epithelia. Among 186 primary carcinomas surveyed by RNA in situ hybridization, hSef expression was undetectable in 116 cases including 72/99 (73%) breast, 11/16 (69%) thyroid, 16/31 (52%) prostate and 17/40 (43%) ovarian carcinomas. Moderate reduction of expression was observed in 17/186, and marked reduction in 40/186 tumors. Only 13/186 cases including 12 low-grade and one intermediate grade tumor retained high hSef expression. The association of hSef downregulation and tumor progression was statistically significant (P<0.001). Functionally, ectopic expression of hSef suppressed proliferation of breast carcinoma cells, whereas inhibition of endogenous hSef expression accelerated fibroblast growth factor and epidermal growth factor-dependent proliferation of cervical carcinoma cells. The inhibitory effect of hSef on cell proliferation combined with consistent downregulation in human carcinoma indicates a tumor suppressor-like role for hSef, and implicates loss of hSef expression as a common mechanism in epithelial neoplasia.


Subject(s)
Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Interleukin/physiology , Breast Neoplasms , Cell Division/physiology , Cell Line, Tumor , Down-Regulation , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Ovarian Neoplasms , Prostatic Neoplasms , Receptors, Interleukin/genetics , Signal Transduction , Thyroid Neoplasms , Tumor Suppressor Proteins/physiology
2.
Oncogene ; 25(4): 609-21, 2006 Jan 26.
Article in English | MEDLINE | ID: mdl-16158046

ABSTRACT

Gli family members mediate constitutive Hedgehog signaling in the common skin cancer, basal cell carcinoma (BCC). Snail/Snai1 is rapidly induced by Gli1 in vitro, and is coexpressed with Gli1 in human hair follicles and skin tumors. In the current study, we generated a dominant-negative allele of Snail, SnaZFD, composed of the zinc-finger domain and flanking sequence. In promoter-reporter assays, SnaZFD blocked the activity of wild-type Snail on the E-cadherin promoter. Snail loss-of-function mediated by SnaZFD or by one of several short hairpin RNAs inhibited transformation of RK3E epithelial cells by Gli1. Conversely, enforced expression of Snail promoted transformation in vitro by Gli1, but not by other genes that were tested, including Notch1, ErbB2, and N-Ras. As observed for Gli1, wild-type Snail repressed E-cadherin in RK3E cells and induced blebbing of the cytoplasmic membrane. Induction of a conditional Gli1 transgene in the basal keratinocytes of mouse skin led to rapid upregulation of Snail transcripts and to cell proliferation in the interfollicular epidermis. Established Gli1-induced skin lesions exhibited molecular similarities to BCC, including loss of E-cadherin. The results identify Snail as a Gli1-inducible effector of transformation in vitro, and an early Gli1-responsive gene in the skin.


Subject(s)
Cell Transformation, Neoplastic , Kruppel-Like Transcription Factors/physiology , Transcription Factors/physiology , Animals , Base Sequence , Carcinoma, Basal Cell/etiology , Cell Cycle , Hyperplasia , Mice , Mice, Inbred C57BL , Molecular Sequence Data , RNA, Small Interfering/pharmacology , Skin/pathology , Skin Neoplasms/etiology , Snail Family Transcription Factors , Transcription Factors/genetics , Zinc Finger Protein GLI1
3.
J Pathol ; 195(3): 343-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11673832

ABSTRACT

The expression of all four ErbB receptors was compared by immunohistochemistry, using receptor-specific polyclonal antisera, in 32 invasive, 11 in situ carcinomas, six benign lesions, and 22 samples of histologically normal mucosa adjacent to specimens of carcinoma originating from oral cavity epithelium. Among invasive and in situ carcinoma, EGFR expression was the most prevalent (in 29/32 and 8/11 cases, respectively) followed by ErbB2 (17/32 and 2/11) and ErbB4 (9/32 and 1/10), while ErbB3 was only detected in invasive tumours (12/32). Specific patterns included invasive tumours with expression of EGFR (8/32) or ErbB4 (1/32) alone, as well as different receptor combinations (EGFR+ErbB2, EGFR+ErbB4, EGFR+ErbB2+ErbB3, EGFR+ErbB2+ErbB4, and all four receptors). Simultaneous expression of three or four ErbB receptors correlated with tumour invasion (p=2.2x10(-4)) and localized in the intermediate epithelial cell layer of well and moderately differentiated tumours. No other significant correlation with clinico-pathological features was noticed. Some benign lesions and histologically normal mucosa adjacent to carcinomas showed weak immunostaining of EGFR (10/28), ErbB2 (4/28) or ErbB4 (3/28). By comparison, overexpression, as indicated by increased staining intensity, was observed in invasive tumours for EGFR (18/32), ErbB2 (8/32), ErbB4 (3/32), and ErbB3 (3/32). Statistical evaluation demonstrated a significant association of EGFR or ErbB2 overexpression with invasive carcinoma when compared with benign lesions and apparently normal epithelium (p=5.2x10(-7) and p=5x10(-3), respectively). Tumour-specific overexpression of ErbB receptors and their co-expression, most frequently involving EGFR and ErbB2, in the same cell layer of neoplastic epithelium, implicate receptor heterodimers in the pathogenesis of oral squamous carcinoma.


Subject(s)
Carcinoma, Squamous Cell/chemistry , Mouth Neoplasms/chemistry , Receptor Protein-Tyrosine Kinases/analysis , Carcinoma, Squamous Cell/pathology , Epithelium/chemistry , ErbB Receptors/analysis , Humans , Immunohistochemistry/methods , Mouth Mucosa , Mouth Neoplasms/pathology , Neoplasm Invasiveness , Receptor, ErbB-2/analysis , Receptor, ErbB-3/analysis , Receptor, ErbB-4 , Uterine Cervical Dysplasia/chemistry
4.
Am J Pathol ; 156(4): 1417-24, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10751365

ABSTRACT

Investigation of ErbB2 immunity in human breast cancer employing recombinant expression sources in immunoblot analysis revealed ErbB2-specific antibodies of the IgG isotype in sera of 14 of 71 cancer patients and 1 of 31 normal donors. Reactivity was confirmed on ErbB2-specific immunoprecipitates. Independent evidence of existing ErbB2 immunity was obtained after in vitro transformation of peripheral blood leukocytes from six positive patients. Furthermore, in vitro immortalization of B-lymphocytes unmasked existent ErbB2 immunity in 1 of 8 patients negative for ErbB2 serum antibodies. Determining shed ErbB2 extracellular domain as an indirect measure of tumor burden in ErbB2-positive malignancy, elevated serum levels were observed in 16 of 71 breast cancer and 1 of 31 normal donor sera. Strikingly, existing ErbB2 immunity correlated significantly with elevated shed ErbB2 ectodomain among the patients analyzed. Incidence of both ErbB2 immunity and elevated ErbB2 extracellular domain increased with a progressed disease stage and was significantly associated with metastatic breast cancer. These observations implicate soluble ErbB2 amounts in vivo in the development of ErbB2 immunity in breast cancer. They further project serum analysis of ErbB2 immunity and soluble ectodomain as potential markers of disease progression in ErbB2-positive malignancy.


Subject(s)
Breast Neoplasms/immunology , Receptor, ErbB-2/immunology , 3T3 Cells , Animals , Antibodies/blood , Antibody Formation , B-Lymphocytes/metabolism , Breast Neoplasms/blood , Breast Neoplasms/physiopathology , Cell Line, Transformed , Female , Humans , Mice , Protein Structure, Tertiary , Receptor, ErbB-2/genetics , Receptor, ErbB-2/metabolism , Solubility
5.
Int J Oncol ; 16(2): 221-30, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10639563

ABSTRACT

The profile of genetic alterations in four breast carcinoma cell lines, SK-BR-3, BT-474, MDA-MB361 and ZR-75-1 was examined by comparative genomic hybridization, G-band karyotyping, reverse chromosome painting and fluorescence in situ hybridization of single-copy genes. These lines are aneuploid with complex structural rearrangements and have DNA copy-number imbalances involving multiple sites that include amplification of ERBB-2 and MYC proto-oncogenes which are implicated in breast cancer pathogenesis. A novel site of high level amplification was mapped on chromosome 15. All lines were tumorigenic in nude mice, however, the latency and the incidence of tumor formation varied; SK-BR-3 and MDA-MB361 produced tumors in a shorter time and had a higher total number of genomic imbalances compared to BT-474 and ZR-75-1 cells. Tumor cell behavior in vivo was not reflected by the rate of in vitro cell proliferation. Underrepresentation on the long arm of chromosome 18 was the sole alteration that correlated with an increased tumorigenicity. Chromosome 18q is rich in tumor suppressor genes and its loss is prevalent in primary node-positive breast tumors. Cell lines with monoclonal populations preserve the genetic characteristics of the primary tumor and their use may facilitate the detection of specific alterations associated with breast cancer progression.


Subject(s)
Breast Neoplasms/genetics , Tumor Cells, Cultured , Animals , Chromosome Aberrations/genetics , Chromosome Disorders , Chromosomes, Human, Pair 18/genetics , Female , Genes, Tumor Suppressor/genetics , Humans , Karyotyping , Mice , Mice, Nude , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism
6.
J Biol Chem ; 274(27): 19465-72, 1999 Jul 02.
Article in English | MEDLINE | ID: mdl-10383463

ABSTRACT

In an effort to isolate novel growth factors, we identified a human protein, designated Sk, that co-eluted with Neuregulin during chromatographic separation of conditioned medium from the SK-LMS-1 human leiomyosarcoma cell line. Degenerate oligonucleotides based on amino-terminal sequence analysis of the purified protein were used to isolate the corresponding cDNA from a library generated from this cell line. Sk is a novel 266-amino acid protein that contains a signal peptide sequence and two cysteine-rich domains with no similarity to other known growth factors. A single major 2-kilobase transcript was expressed in several embryonic tissues. Transfection of mammalian cells demonstrated that the protein was secreted and expressed as a doublet of approximately 35 kDa. In vitro translation and endoglycosylase analysis indicated that this doublet, which was also observed in cells expressing the endogenous protein, arises from posttranslational modification. A search of the GenBankTM data base revealed a match of Sk with Dkk-1, which is a novel secreted protein required for head induction in amphibian embryos and a potent Wnt inhibitor. When coexpressed with Wnt-2 in NIH3T3 cells, human Sk/Dkk-1 caused reversion of Wnt-2 induced morphological alterations and inhibited the Wnt-2 induced increase in uncomplexed beta-catenin levels. These results provide biochemical evidence that human Sk/Dkk-1 antagonizes Wnt signaling upstream of its effect on beta-catenin regulation.


Subject(s)
Proteins/isolation & purification , Proto-Oncogene Proteins/antagonists & inhibitors , Signal Transduction , Zebrafish Proteins , 3T3 Cells , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , Humans , Intercellular Signaling Peptides and Proteins , Mice , Molecular Sequence Data , Proteins/chemistry , Transfection , Wnt Proteins , Wnt2 Protein
7.
Oncogene ; 18(6): 1267-75, 1999 Feb 11.
Article in English | MEDLINE | ID: mdl-10022808

ABSTRACT

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.


Subject(s)
Antibodies, Neoplasm/blood , ErbB Receptors/immunology , Proto-Oncogene Proteins/immunology , Receptor, ErbB-2/immunology , Antigens, Neoplasm/genetics , Antigens, Neoplasm/immunology , Carcinoma/immunology , ErbB Receptors/isolation & purification , Humans , Immunoglobulin Isotypes , Immunohistochemistry , Lymphoma/immunology , Neoplasms, Glandular and Epithelial/immunology , Proto-Oncogene Proteins/isolation & purification , Receptor, ErbB-2/isolation & purification , Receptor, ErbB-3 , Receptor, ErbB-4 , Recombinant Proteins/immunology
8.
EMBO J ; 15(11): 2717-25, 1996 Jun 03.
Article in English | MEDLINE | ID: mdl-8654369

ABSTRACT

The RET proto-oncogene encodes a receptor with tyrosine kinase activity (RET) that is involved in several neoplastic and non-neoplastic diseases. Oncogenic activation of RET, achieved by different mechanisms, is detected in a sizeable fraction of human thyroid tumors, as well as in multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma tumoral syndromes. Germline mutations of RET have also been associated with a non-neoplastic disease, the congenital colonic aganglionosis, i.e. Hirschsprung's disease (HSCR). To analyse the impact of HSCR mutations on RET function, we have introduced into wild-type RET and activated RET(MEN2A) and RET(MEN2B) alleles three missense mutations associated with HSCR. Here we show that the three mutations caused a loss of function of RET when assayed in two model cell systems, NIH 3T3 and PC12 cells. The effect of different HSCR mutations was due to different molecular mechanisms. The HSCR972 (Arg972-->Gly) mutation, mapping in the intracytoplasmic region of RET, impaired its tyrosine kinase activity, while two extracellular mutations, HSCR32 (Ser32-->Leu) and HSCR393 (Phe393-->Leu), inhibited the biological activity of RET by impairing the correct maturation of the RET protein and its transport to the cell surface.


Subject(s)
Drosophila Proteins , Hirschsprung Disease/genetics , Immediate-Early Proteins , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , 3T3 Cells , Animals , Base Sequence , DNA Primers/chemistry , DNA-Binding Proteins/genetics , Early Growth Response Protein 1 , Gene Expression Regulation, Neoplastic , Humans , Mice , Molecular Sequence Data , Nerve Growth Factors , Neuropeptides , PC12 Cells , Point Mutation , Proteins/genetics , Proto-Oncogene Mas , Proto-Oncogene Proteins c-ret , RNA, Messenger/genetics , Rats , Structure-Activity Relationship , Transcription Factors/genetics
9.
J Biol Chem ; 271(9): 5251-7, 1996 Mar 01.
Article in English | MEDLINE | ID: mdl-8617810

ABSTRACT

Four transmembrane tyrosine kinases constitute the ErbB receptor family: the epidermal growth factor (EGF) receptor, ErbB-2, ErbB-3, and ErbB-4. We have measured the endocytic capacities of all four members of the EGF receptor family, including ErbB-3 and ErbB-4, which have not been described previously. EGF-responsive chimeric receptors containing the EGF receptor extracellular domain and different ErbB cytoplasmic domains (EGFR/ErbB) have been employed. The capacity of these growth factor-receptor complexes to mediate 125I-EGF internalization, receptor down-regulation, receptor degradation, and receptor co-immunoprecipitation with AP-2 was assayed. In contrast to the EGF receptor, all EGFR/ErbB receptors show impaired ligand-induced rapid internalization, down-regulation, degradation, and AP-2 association. Also, we have analyzed the heregulin-responsive wild-type ErbB-4 receptor, which does not mediate the rapid internalization of 125I-heregulin, demonstrates no heregulin-regulated receptor degradation, and fails to form association complexes with AP-2. Despite the substantial differences in ligand-induced receptor trafficking between the EGF and ErbB-4 receptors, EGF and heregulin have equivalent capacities to stimulate DNA synthesis in quiescent cells. These results show that the ligand-dependent down-regulation mechanism of the EGF receptor, surprisingly, is not a property of any other known ErbB receptor family member. Since endocytosis is thought to be an attenuation mechanism for growth factor-receptor complexes, these data imply that substantial differences in attenuation mechanisms exist within one family of structurally related receptors.


Subject(s)
Endocytosis , Epidermal Growth Factor/pharmacology , ErbB Receptors/metabolism , ErbB Receptors/physiology , Neuregulin-1 , Proto-Oncogene Proteins/physiology , Receptor, ErbB-2/physiology , 3T3 Cells , Animals , Base Sequence , Carrier Proteins/pharmacology , DNA Primers , DNA Replication/drug effects , Down-Regulation , Endocytosis/drug effects , Epidermal Growth Factor/metabolism , ErbB Receptors/drug effects , ErbB Receptors/isolation & purification , Glycoproteins/pharmacology , Humans , Kinetics , Mice , Molecular Sequence Data , Neuregulins , Polymerase Chain Reaction , Proto-Oncogene Proteins/drug effects , Proto-Oncogene Proteins/isolation & purification , Receptor, ErbB-2/drug effects , Receptor, ErbB-2/isolation & purification , Receptor, ErbB-3 , Receptor, ErbB-4 , Recombinant Fusion Proteins/drug effects , Recombinant Fusion Proteins/metabolism , Transfection
10.
Gene ; 166(2): 277-80, 1995 Dec 12.
Article in English | MEDLINE | ID: mdl-8543175

ABSTRACT

alpha-Galactosidase A (alpha-D-galactoside galactohydrolase, EC 3.2.1.22; alpha GalA) is a lysosomal enzyme that hydrolyses the alpha-D-galactosyl residues from glycosphingolipids. Fabry disease, an inhibited X-linked recessive human metabolic disorder, results from a mutation in the alpha GalA gene at Xq22. As a prerequisite for generating a mouse model of Fabry disease by gene targeting, we have isolated and characterized the mouse alpha GalA gene and cDNA. A cloned mouse alpha GalA cDNA encoded a putative precursor protein of 419 amino acids (aa), including a 31-aa signal peptide (SP). The deduced aa sequence showed high homology (79%) with the human alpha GalA protein. Nucleotide sequence analysis of genomic clones revealed that the overall structure and organization of the gene was very similar to that of human alpha GalA. All exon-intron splice junctions conformed to the GT/AG consensus sequence. Comparison of genomic and cDNA sequences revealed the occurrence of two putative polyadenylation signals whose alternative use results in the two mouse alpha GalA transcripts of 1.4 and 3.6 kb. The 5'-flanking region of mouse alpha GalA had no typical TATA box. Several putative promoter-associated elements including Sp1, AP1 and a potential cAMP-responsive element (CRE) were identified. Northern blot analysis revealed the widespread tissue distribution of mouse alpha GalA transcripts. Lower expression levels, however, were observed in some tissues, implying tissue-specific differences in alpha GalA promoter function.


Subject(s)
alpha-Galactosidase/genetics , Amino Acid Sequence , Animals , Base Sequence , Exons , Gene Expression , Genes , Humans , Introns , Mice , Molecular Sequence Data , RNA, Messenger/genetics , Regulatory Sequences, Nucleic Acid , Tissue Distribution
11.
J Biol Chem ; 270(28): 16510-3, 1995 Jul 14.
Article in English | MEDLINE | ID: mdl-7622453

ABSTRACT

The cytokine signaling pathways that activate the Janus family of tyrosine kinases (Jaks) and the "signal transducers and activators of transcription" (Stats) have been well characterized in mammalian systems. Work shown here provides evidence that an analogous signaling pathway exists in Drosophila melanogaster. Because many of the ligand-receptor pairs in Drosophila have not been fully characterized, it was necessary to bypass the receptor stimulation event that normally triggers intracellular Jak/Stat activation. This was done by treating Drosophila Schneider 2 cells with vanadate/peroxide, which has been shown to closely mimic some signaling events triggered by interferon gamma, including the activation of Jak1, Jak2, and the Stat1 alpha protein. Evidence presented here demonstrates that vanadate/peroxide can induce a gamma response region binding complex in Drosophila Schneider 2 cells. This complex contains two phosphoproteins of 100 and 150 kDa, respectively, and shares many features with the vanadate/peroxide-stimulated binding complex in the mammalian system. Southern blot analysis of genomic DNA using the src homology domain 2 (SH2) of Stat1 alpha confirms the presence of a related gene in the Drosophila genome.


Subject(s)
DNA-Binding Proteins/analysis , Drosophila melanogaster/chemistry , Trans-Activators/analysis , Animals , Base Sequence , Blotting, Southern , Drosophila melanogaster/genetics , Humans , Molecular Sequence Data , Phosphorylation , Promoter Regions, Genetic , Tyrosine/metabolism , Vanadates/pharmacology
12.
Oncogene ; 10(9): 1813-21, 1995 May 04.
Article in English | MEDLINE | ID: mdl-7538656

ABSTRACT

In the present study we demonstrate that erbB-3 and erbB-2 cooperate in neoplastic transformation. Under conditions in which neither gene alone induced transformation, they readily transformed NIH3T3 cells if co-expressed. Furthermore, at high expression levels of ErbB2 which cause transformation, ErbB3 enhanced focus formation by one order of magnitude. Synergy required an intact ErbB2 extracellular domain and tyrosine kinase activity. Cooperation between ErbB3 and ErbB2 involved heterodimerization and increased tyrosine phosphorylation of ErbB3. Signaling by the heterodimer resulted in increased PI 3-kinase recruitment as well as quantitative and qualitative differences in substrate phosphorylation. Evidence for signaling by an active ErbB3-ErbB2 heterodimer in four mammary tumor cell lines indicated relevance of this mechanism for human neoplasia. Our detection of the NDF/heregulin transcript in NIH3T3 cells implicates an autocrine loop involving this ligand in signaling by the ErbB3-ErbB2 heterodimer in the model system, whereas heregulin-independent mechanisms likely exist for cooperative signaling by ErbB3 and ErbB2 chronically activated in some human mammary carcinomas.


Subject(s)
Breast Neoplasms/genetics , Cell Transformation, Neoplastic , ErbB Receptors/physiology , Proto-Oncogene Proteins/physiology , Receptor, ErbB-2/physiology , 3T3 Cells , Animals , Base Sequence , DNA Primers/chemistry , Gene Expression Regulation, Neoplastic , Genes, erbB , Glycoproteins/physiology , Ligands , Mice , Molecular Sequence Data , Neuregulins , Phosphatidylinositol 3-Kinases , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Phosphotyrosine , Protein-Tyrosine Kinases/metabolism , RNA, Messenger/genetics , Receptor Aggregation , Receptor, ErbB-3 , Signal Transduction , Tyrosine/analogs & derivatives , Tyrosine/metabolism
13.
Oncogene ; 10(6): 1235-7, 1995 Mar 16.
Article in English | MEDLINE | ID: mdl-7700649

ABSTRACT

The HER4/erbB-4 gene has been isolated as the fourth member of the human EGFR subfamily of tyrosine kinases and has been reported to encode a receptor for NDF/heregulin. In the present study we determined the chromosomal location of the HER4/erbB-4 gene within the human genome. Using human cDNA probes in fluorescence in situ hybridization (FISH), we mapped the HER4/erbB-4 gene to human chromosome 2q33.3-34. This finding established that also the HER4/erbB-4 gene is located in close vicinity of homeobox and collagen gene loci, as is the case for the related EGFR, erbB-2/neu and erbB-3. Aberrations of this chromosomal region associated with T cell leukemias and lymphomas as well as alveolar rhabdomyosarcomas raise the possibility that HER4/erbB-4 might be activated in these tumour types.


Subject(s)
Chromosomes, Human, Pair 2 , ErbB Receptors/genetics , Chromosome Mapping , DNA, Complementary , Humans , In Situ Hybridization, Fluorescence , Receptor, ErbB-4
14.
Science ; 267(5196): 381-3, 1995 Jan 20.
Article in English | MEDLINE | ID: mdl-7824936

ABSTRACT

Multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma are dominantly inherited cancer syndromes. All three syndromes are associated with mutations in RET, which encodes a receptor-like tyrosine kinase. The altered RET alleles were shown to be transforming genes in NIH 3T3 cells as a consequence of constitutive activation of the RET kinase. The MEN2A mutation resulted in RET dimerization at steady state, whereas the MEN2B mutation altered RET catalytic properties both quantitatively and qualitatively. Oncogenic conversion of RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.


Subject(s)
Cell Transformation, Neoplastic/genetics , Drosophila Proteins , Multiple Endocrine Neoplasia Type 2a/genetics , Multiple Endocrine Neoplasia Type 2b/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogenes , Receptor Protein-Tyrosine Kinases/genetics , 3T3 Cells , Alleles , Animals , Genetic Vectors , Humans , Mice , Mutation , Phosphorylation , Proto-Oncogene Proteins/chemistry , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-ret , Receptor Protein-Tyrosine Kinases/chemistry , Receptor Protein-Tyrosine Kinases/metabolism , Substrate Specificity , Transfection , Tumor Cells, Cultured
15.
Oncogene ; 9(10): 3057-61, 1994 Oct.
Article in English | MEDLINE | ID: mdl-8084614

ABSTRACT

We have previously isolated the coding sequence for a novel substrate for tyrosine kinases, eps8, from NIH3T3 fibroblasts. Eps8 was phosphorylated in vivo by several receptor tyrosine kinases (RTKs) and, upon overexpression, was able to enhance EGFR-mediated mitogenic signaling in NIH3T3 cells. To gain understanding of eps8 function as well as its role in normal and neoplastic proliferation, we cloned the human eps8 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. In addition to a previously identified SH3 domain, the predicted amino acid sequence of human eps8 revealed a non-random distribution of prolines, clustered in a way to suggest SH3-binding sites and a putative PH domain. Eps8 was expressed in all epithelial and fibroblastic lines examined and in some, but not all, hematopoietic cells. An essential function of eps8 in cell growth regulation was underscored by its conservation during evolution, where eps8-related sequences were detected as early as in Saccharomyces cerevisiae. Finally, the human EPS8 locus was mapped to chromosome 12q23-q24.


Subject(s)
Biological Evolution , Chromosomes, Human, Pair 12 , Conserved Sequence , Proteins/genetics , 3T3 Cells , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Animals , Chromosome Mapping , Cytoskeletal Proteins , Humans , Intracellular Signaling Peptides and Proteins , Mice , Molecular Sequence Data , Sequence Homology, Amino Acid
16.
Oncogene ; 9(6): 1591-7, 1994 Jun.
Article in English | MEDLINE | ID: mdl-8183552

ABSTRACT

Employing an expression cloning approach for tyrosine kinase substrates, we have previously isolated the coding sequence for a novel putative EGFR substrate, eps15, from NIH3T3 fibroblasts. Eps15 displayed a receptor-specific pattern of tyrosine phosphorylation in vivo and was able to transform NIH3T3 cells upon overexpression. To gain understanding of eps15 function as well as its role in normal and neoplastic proliferation, we cloned the human eps15 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. The close structural similarity of human eps15 with the murine homologue is indicated by 89% and 90% identity of nucleotide and predicted amino acid sequences, respectively. Using the human eps15 coding sequence as probe, we demonstrate that eps15 is member of a gene family that is highly conserved during evolution. An essential function of eps15 in cell growth regulation is underscored by our observation of ubiquitous expression at the transcript and the protein level in normal and malignant human cells. The human EPS15 locus maps to chromosome 1p31-p32, a region involved in deletion in neuroblastoma, translocations in acute lymphoblastic leukemia, and exhibiting a fragile site.


Subject(s)
Calcium-Binding Proteins/genetics , Chromosomes, Human, Pair 1 , Phosphoproteins/genetics , Signal Transduction , 3T3 Cells , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Animals , Base Sequence , Biological Evolution , Calcium-Binding Proteins/chemistry , Chromosome Mapping , Conserved Sequence , DNA, Complementary/chemistry , Humans , Intracellular Signaling Peptides and Proteins , Mice , Molecular Sequence Data , Phosphoproteins/chemistry
17.
Mol Cell Biol ; 14(1): 492-500, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8264617

ABSTRACT

Recombinant expression of a chimeric EGFR/ErbB-3 receptor in NIH 3T3 fibroblasts allowed us to investigate cytoplasmic events associated with ErbB-3 signal transduction upon ligand activation. An EGFR/ErbB-3 chimera was expressed on the surface of NIH 3T3 transfectants as two classes of receptors possessing epidermal growth factor (EGF) binding affinities comparable to those of the wild-type EGF receptor (EGFR). EGF induced autophosphorylation in vivo of the chimeric receptor and DNA synthesis of EGFR/ErbB-3 transfectants with a dose response similar to that of EGFR transfectants. However, the ErbB-3 and EGFR cytoplasmic domains exhibited striking differences in their interactions with several known tyrosine kinase substrates. We demonstrated strong association of phosphatidylinositol 3-kinase activity with the chimeric receptor upon ligand activation comparable in efficiency with that of the platelet-derived growth factor receptor, while the EGFR exhibited a 10- to 20-fold-lower efficiency in phosphatidylinositol 3-kinase recruitment. By contrast, both phospholipase C gamma and GTPase-activating protein failed to associate with or be phosphorylated by the ErbB-3 cytoplasmic domain under conditions in which they coupled with the EGFR. In addition, though certain signal transmitters, including Shc and GRB2, were recruited by both kinases, EGFR and ErbB-3 elicited tyrosine phosphorylation of distinct sets of intracellular substrates. Thus, our findings show that ligand activation of the ErbB-3 kinase triggers a cytoplasmic signaling pathway that hitherto is unique within this receptor subfamily.


Subject(s)
ErbB Receptors/metabolism , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Proto-Oncogene Proteins/metabolism , Signal Transduction/physiology , 3T3 Cells/metabolism , Animals , ErbB Receptors/genetics , GTPase-Activating Proteins , Mice , Phosphatidylinositol 3-Kinases , Proteins/metabolism , Proto-Oncogene Proteins/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Transfection , Type C Phospholipases/metabolism
18.
Proc Natl Acad Sci U S A ; 90(7): 2900-4, 1993 Apr 01.
Article in English | MEDLINE | ID: mdl-8464905

ABSTRACT

The predicted human erbB-3 gene product is closely related to epidermal growth factor receptor (EGFR) and erbB-2, which have been implicated as oncogenes in model systems and human neoplasia. We expressed the erbB-3 coding sequence in NIH 3T3 fibroblasts and identified its product as a 180-kDa glycoprotein, gp180erbB-3. Tunicamycin and pulse-chase experiments revealed that the mature protein was processed by N-linked glycosylation of a 145-kDa erbB-3 core polypeptide. The intrinsic catalytic function of gp180erbB-3 was shown by its ability to autophosphorylate in vitro. Ligand-dependent signaling of its cytoplasmic domain was established employing transfectants that express a chimeric EGFR/erbB-3 protein, gp180EGFR/erbB-3. EGF induced tyrosine phosphorylation of the chimera and promoted soft agar colony formation of such transfectants. These findings combined with the detection of constitutive tyrosine phosphorylation of gp180erbB-3 in 4 of 12 human mammary tumor cell lines implicate the activated erbB-3 product in the pathogenesis of some human malignancies.


Subject(s)
Breast Neoplasms/enzymology , Breast Neoplasms/genetics , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Amino Acid Sequence , Antibodies, Monoclonal , Base Sequence , Enzyme Activation , Epidermal Growth Factor/pharmacology , ErbB Receptors/genetics , ErbB Receptors/metabolism , Female , Glycosylation , Humans , Immunohistochemistry , Molecular Sequence Data , Oligodeoxyribonucleotides , Oligopeptides/chemical synthesis , Oligopeptides/immunology , Phosphorylation , Protein Processing, Post-Translational , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins/analysis , Proto-Oncogene Proteins/genetics , Receptor, ErbB-3 , Recombinant Fusion Proteins/metabolism , Signal Transduction , Transfection , Tumor Cells, Cultured , Tunicamycin/pharmacology
19.
EMBO J ; 11(11): 3927-33, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1356764

ABSTRACT

The epidermal growth factor (EGF) receptor (EGFR) and the erbB-2 gene product, gp185erbB-2, exhibit distinct abilities to stimulate mitogenesis in different target cells. By using chimeric molecules between these two receptors, we have previously shown that their intracellular juxtamembrane regions are responsible for this specificity. Here we describe a genetically engineered EGFR mutant containing a threonine for arginine substitution at position 662 in the EGFR juxtamembrane domain, corresponding to threonine 694 in gp185erbB-2. This mutant, designated EGFRThr662, displayed affinity for EGF binding and catalytic properties that were indistinguishable from those of the wild type EGFR. However, EGFRThr662 behaved much as gp185erbB-2 in a number of bioassays which readily distinguish between the mitogenic effects of EGFR and gp185erbB-2. Moreover, significant differences were detected in the pattern of intracellular proteins phosphorylated on tyrosine in vivo by EGFR and EGFRThr662 in response to EGF. Thus, small differences in the primary sequence of two closely related receptors have dramatic effects on their ability to couple with mitogenic pathways.


Subject(s)
DNA Replication/drug effects , Epidermal Growth Factor/pharmacology , ErbB Receptors/physiology , Mitogens , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/physiology , Proto-Oncogenes , 3T3 Cells , Amino Acid Sequence , Animals , Arginine , Base Sequence , Codon/genetics , Epidermal Growth Factor/metabolism , ErbB Receptors/genetics , Genetic Vectors , Kinetics , Mice , Molecular Sequence Data , Mutagenesis, Site-Directed , Oligodeoxyribonucleotides , Phosphorylation , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins/genetics , Receptor, ErbB-2 , Repetitive Sequences, Nucleic Acid , Signal Transduction , Threonine , Thymidine/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...